The management of immune thrombocytopenic purpura (ITP) involves several lines of therapy such as corticosteroids and intravenous immunoglobulin. With the emergence of novel therapies such as thrombopoietin receptor agonists (TPO-RAs), there has been a shift in treatment modalities. Eltrombopag and romiplostim have proven to be effective in the management of ITP through clinical studies, but their safety in pregnancy remains uncertain. The purpose of the study is to review the literature to evaluate the safety of TPO-RAs in pregnant women. Ten case reports and a cohort study pertaining to the use of TPO-RAs in pregnancy were obtained. According to the reported cases and prospective study, the use of eltrombopag and romiplostim appears to be relatively safe in the first, second, and third trimesters, as there were no reported congenital malformations. Low fetal birth weight has been observed following the administration of eltrombopag during the second trimester, whereas preterm birth has occurred following the administration of eltrombopag in the third trimester. Eltrombopag and romiplostim seem relatively safe. Further studies are necessary to clarify their safety during pregnancy.
Howaidi, Jude; AlRajhi, Abdullah M.; Howaidi, Ali; AlNajjar, Fouad H.; and Tailor, Imran K.
"Use of Thrombopoietin Receptor Agonists in Pregnancy: A Review of the Literature,"
Hematology/Oncology and Stem Cell Therapy: Vol. 15:
1, Article 1.
Available at: https://www.hosct.org/hematology-oncology-and-stem-cell-therapy/vol15/iss1/1